Apellis (APLS) and Sobi announced the European Medicines Agency has validated an indication extension application for Aspaveli for the ...

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi ® (STO:SOBI) today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli ® (pegcetacoplan) ...

Sobi® and Apellis Pharmaceuticals today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli® (pegcetacoplan) for the treatment of C3 ...

This is the all-new, second-generation Citroen C3 Aircross. Like the car it replaces, it’s essentially a slightly larger, raised version of the standard C3 supermini. It’s based on the same ...

Eleva, a German biopharmaceutical company, and 3PBIOVIAN, a global contract development and manufacturing organization (CDMO), have announced a strategic partnership to enhance the production of Eleva ...

Pegcetacoplan: Apellis Pharmaceuticals Pegcetacoplan is a complement C3 inhibitor that has shown potential in treating Complement 3 Glomerulopathy (C3G) by targeting the dysregulated complement system ...

A Phase 3 clinical trial found that injections of the semaglutide medication once weekly reduced the risk of kidney disease worsening by 24% in people who also had diabetes. It also reduced the ...

A team led by Dr. Erik Larson, vice chair of the Department of Biomedical Sciences, has uncovered the cause of a common kidney disease after eight years of research, a news release from WMed said.

In its early stages, kidney disease may not cause any symptoms or signs. However, as it progresses, it can cause symptoms such as itchy skin, pruritus, and a rash. Around 35.5 million adults in ...

A new strategic alliance between C3.ai and McKinsey & Company will help bring the former's technology to more customers. Two key actions from the new presidential administration are lifting ...